• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890

Introduction to 2-Bromo-5-chloroisonicotinamide (CAS No. 1807220-97-8)

2-Bromo-5-chloroisonicotinamide, identified by its Chemical Abstracts Service (CAS) number 1807220-97-8, is a specialized organic compound that has garnered significant attention in the field of medicinal chemistry and pharmaceutical research. This compound belongs to the class of isonicotinamide derivatives, which are well-known for their versatile biological activities and potential therapeutic applications. The presence of both bromo and chloro substituents on the isonicotinamide backbone enhances its chemical reactivity, making it a valuable scaffold for further structural modifications and functionalization.

The structural features of 2-Bromo-5-chloroisonicotinamide contribute to its unique pharmacological profile. The isonicotinamide moiety is a key pharmacophore found in several FDA-approved drugs, including antibiotics and anti-inflammatory agents. By introducing bromine and chlorine atoms at the 2- and 5-positions, respectively, the compound exhibits altered electronic and steric properties, which can influence its binding affinity to biological targets. This modification opens up possibilities for designing novel molecules with improved efficacy and reduced side effects.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors for various diseases, particularly those involving enzyme inhibition or receptor modulation. 2-Bromo-5-chloroisonicotinamide has been explored as a potential lead compound in this context. Its halogenated structure allows for facile further derivatization through cross-coupling reactions, such as Suzuki-Miyaura or Buchwald-Hartwig couplings, enabling the construction of more complex scaffolds. These reactions are widely employed in drug discovery to introduce aryl or heteroaryl groups, which can enhance target interactions.

One of the most compelling aspects of 2-Bromo-5-chloroisonicotinamide is its utility in medicinal chemistry as a building block for drug development. Researchers have leveraged its scaffold to design molecules targeting various therapeutic areas, including oncology, neurology, and infectious diseases. For instance, studies have demonstrated that halogenated isonicotinamides can exhibit potent activity against bacterial enzymes by mimicking natural substrates or by inducing conformational changes in the enzyme active site. This makes them promising candidates for developing next-generation antibiotics.

The synthesis of 2-Bromo-5-chloroisonicotinamide typically involves multi-step organic transformations starting from commercially available precursors. The introduction of bromine and chlorine atoms can be achieved through electrophilic aromatic substitution reactions or metal-catalyzed halogenation processes. The choice of synthetic route depends on factors such as yield, scalability, and purity requirements. Advanced techniques like flow chemistry have also been employed to optimize these reactions, ensuring high efficiency and reproducibility.

From a computational chemistry perspective, the molecular properties of 2-Bromo-5-chloroisonicotinamide have been extensively studied using quantum mechanical methods. Molecular dynamics simulations have provided insights into its conformational behavior and interactions with biological targets. These studies help in rationalizing experimental observations and guiding the design of more effective derivatives. Additionally, virtual screening techniques have been used to identify potential binding partners for this compound, accelerating the drug discovery process.

The pharmacokinetic profile of 2-Bromo-5-chloroisonicotinamide is another critical aspect that has been investigated. In vitro assays have been conducted to evaluate its solubility, stability, and metabolic degradation pathways. These studies are essential for understanding how the compound behaves within biological systems and for predicting its bioavailability. Furthermore, preclinical studies in cell culture and animal models have provided preliminary evidence of its biological activity, paving the way for further clinical investigations.

In conclusion,2-Bromo-5-chloroisonicotinamide (CAS No. 1807220-97-8) represents a significant advancement in medicinal chemistry due to its versatile structure and potential therapeutic applications. Its halogenated isonicotinamide core offers opportunities for designing novel drugs targeting a wide range of diseases. As research in this field continues to evolve,2-Bromo-5-chloroisonicotinamide is likely to play an increasingly important role in the development of next-generation pharmaceuticals.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)